Today: 9 June 2026
Lockheed Martin stock jumps after hypersonic missile engine test with GE, Stinger-replacement flight milestone

Lockheed Martin stock jumps after hypersonic missile engine test with GE, Stinger-replacement flight milestone

NEW YORK, Jan 14, 2026, 19:15 ET — After-hours

  • Lockheed Martin shares climbed 2.6% in late trading amid widespread gains across U.S. defense stocks
  • Lockheed and GE Aerospace announced successful tests of a new ramjet design targeting hypersonic missile applications
  • Citi raised its price target for Lockheed to $592 ahead of the Jan. 29 earnings call

Lockheed Martin shares jumped 2.6% in after-hours trading Wednesday following news that the defense giant and GE Aerospace wrapped up engine tests for a new ramjet designed for hypersonic missiles. Northrop Grumman climbed 4.4%, RTX edged up 2.4%, and General Dynamics gained 0.7%. GE Aerospace, however, slipped 2.5%.

This update is crucial as investors seek clear signs that U.S. weapons makers are accelerating progress on next-gen missile technology and expanding the supply chains needed to support it. Hypersonic programs come with high costs and complexity, but any breakthrough news can quickly sway sentiment in a sector where contract timelines stretch over years.

The Pentagon’s move to pump $1 billion into L3Harris Technologies’ rocket motor division has sharpened that focus. This rare direct investment aims to secure propulsion for weapons like Tomahawks and Patriot interceptors. Officials described it as a shift toward backing critical suppliers outright. Separately, the department struck a seven-year deal with Lockheed last week to boost PAC-3 missile production from around 600 to 2,000 units annually.

Lockheed and GE have conducted a series of tests proving the viability of a liquid-fueled “rotating detonation” ramjet — an air-breathing engine that uses detonation waves instead of conventional combustion to burn fuel — designed for missiles capable of hypersonic speeds, exceeding five times the speed of sound. GE’s Mark Rettig said the tests “exceeded expectations,” while Lockheed’s Randy Crites emphasized their goal of delivering “affordable capability” with “extended range at extreme speeds.” Media – Lockheed Martin

Lockheed announced it wrapped up the first flight test of its Next-Generation Short-Range Interceptor the day before, aiming to replace the Stinger missile. Conducted at White Sands Missile Range, the test confirmed the system’s performance and advanced critical subsystems. The design features an “open systems architecture,” allowing hardware and software updates via a plug-and-play setup. “Our team’s shared mission, innovative approach and agility were essential,” said Crites. Chris Murphy, the business development lead, added the controlled flight test series was completed “in less than six months.” Media – Lockheed Martin

Citi’s John Godyn bumped his price target for Lockheed up to $592 from $505, maintaining a Neutral rating. He noted that “the sector’s momentum is likely to continue through the first half of 2026.” Remember, a price target reflects where an analyst thinks the stock might trade over the next year, not a promise. TipRanks

Yet the short-term wager isn’t without its usual pitfalls: hypersonic propulsion development can hit snags in both engineering and test ranges. The Stinger-replacement program remains in early flight testing, with no production green light yet. Any delays or cost overruns could quickly shift contractor sentiment, particularly as Washington steps up its scrutiny of industrial execution.

Lockheed plans to release its fourth-quarter and full-year 2025 results before the market opens on Jan. 29. The earnings call, featuring CEO Jim Taiclet and CFO Evan Scott, is scheduled for 8:30 a.m. ET.

Traders will be watching to see if Wednesday’s gains stick through Thursday. Attention also turns to Lockheed for any fresh test updates or new details on contracts ahead of the Jan. 29 call.

Stock Market Today

  • U.S. Inflation Poised to Exceed 4% for First Time Since 2023, Pressures Mount on Fed
    June 9, 2026, 10:06 AM EDT. U.S. inflation is set to surpass 4% for the first time since 2023, signaling rising consumer prices and intensifying economic pressures. This uptick, measured by the year-over-year increase in the Consumer Price Index (CPI), highlights renewed challenges for the Federal Reserve (Fed) as it grapples with balancing inflation control against economic growth. The rise in inflation may influence the Fed's monetary policy decisions amid concerns over sustained price increases impacting households and businesses for the remainder of the year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Morgan Stanley stock slips before earnings as Wall Street digests big-bank signals
Previous Story

Morgan Stanley stock slips before earnings as Wall Street digests big-bank signals

NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown
Next Story

NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown

Go toTop